Fertilization and live birth rates followeing conventional IVF versus ICSI in non male factor: a prospective randomized study using sibling oocytes

Objective. To investigate the outcomes of intracytoplasmic sperm injection (ICSI) cycles where sibling oocytes from a single donor were split between two recipients based on strict sperm morphology.Methods. Retrospective cohort study. All ICSI cycles had one donor’s oocytes split between two recipients in a 1 : 1 ratio based on strict sperm morphology, that is, one male partner had morphology of 0% and the other had morphology of >1%. Fertilization, positive hCG, clinical pregnancy, spontaneous miscarriage, and live birth rates of the aforementioned groups were compared.Results. The baseline characteristics of the two groups (n=103), including semen parameters of the male partners, were comparable. There was no difference in the fertilization rates when comparing the 0% group to the >1% group (78.7% versus 81.6%;P=0.66). The overall positive hCG, clinical pregnancy, spontaneous miscarriage, and live birth rates for the 0% group were 61.2%, 49.5%, 10.7%, and 38.8%, respectively. The corresponding rates in the >1% group were positive hCG (63.1%), clinical pregnancy (55.3%), spontaneous miscarriage (7.77%), and live birth (46.6%).Conclusions. The fertilization and pregnancy outcomes of ICSI cycles for strict sperm morphology of 0% versus morphology of >1% are equivalent. These results can provide reassurance to couples undergoing ICSI for severe teratospermia.

Download Full-text

Comparison of in vitro fertilisation/intracytoplasmic sperm injection on live birth rates in couples with non-male factor infertility and advanced maternal age

Journal of Assisted Reproduction and Genetics ◽

10.1007/s10815-020-02026-8 ◽

2021 ◽

Author(s):

Nicole O. McPherson ◽

Andrew D. Vincent ◽

Leanne Pacella-Ince ◽

Kelton Tremellen

Keyword(s):

Live Birth ◽

Intracytoplasmic Sperm Injection ◽

Maternal Age ◽

Advanced Maternal Age ◽

In Vitro Fertilisation ◽

Male Factor Infertility ◽

Male Factor ◽

Birth Rates ◽

Live Birth Rates

Download Full-text

Correction to: Comparison of in vitro fertilisation/intracytoplasmic sperm injection on live birth rates in couples with non-male factor infertility and advanced maternal age

Journal of Assisted Reproduction and Genetics ◽

10.1007/s10815-021-02076-6 ◽

2021 ◽

Vol 38 (3) ◽

pp. 679-679

Author(s):

Nicole O. McPherson ◽

Andrew D. Vincent ◽

Leanne Pacella-Ince ◽

Kelton Tremellen

Keyword(s):

Live Birth ◽

Intracytoplasmic Sperm Injection ◽

Maternal Age ◽

Advanced Maternal Age ◽

In Vitro Fertilisation ◽

Male Factor Infertility ◽

Male Factor ◽

Birth Rates ◽

Live Birth Rates

Download Full-text

Differences in ICSI Utilization Rates Among States With Insurance Mandates for ART Coverage

10.21203/rs.3.rs-970725/v1 ◽

2021 ◽

Author(s):

Pavel Zagadailov ◽

Kyung S CHO ◽

David B SEIFER

Keyword(s):

Live Birth ◽

Statistical Significance ◽

Age Groups ◽

Bonferroni Correction ◽

Male Factor ◽

Birth Rates ◽

Preimplantation Genetic Testing ◽

Insurance Mandates ◽

Live Birth Rates ◽

Insurance Mandate

Abstract Background Assisted reproductive technology (ART) insurance mandates promote more selective utilization of ART clinic resources including intracytoplasmic sperm injection (ICSI). Our objective was to examine whether ICSI utilization differs by state insurance mandates for ART coverage and assess if such a difference is associated with male factor, preimplantation genetic testing (PGT), and/or live birth rates. Methods In this retrospective analysis of the Centers for Disease Control (CDC) data from 2018, ART clinics in ART-mandated states (n=8, AR, CT, HI, IL, MD, MA, NJ, RI) were compared individually to one another and with non-mandated states in aggregate (n=42) for use of ICSI, male factor, PGT, and live birth rates. ANOVA was used to evaluate differences between ART-mandated states and non-mandated states. Individual ART-mandated states were compared using Welch t-tests. Statistical significance was determined by Bonferroni Correction. Results There were significant differences in ICSI rates (%, mean ± SD) between MA (53.3 ± 21.3) and HI (90.7 ± 19.6), p = 0.028; IL (86.5 ± 18.7) and MA, p = 0.002; IL and MD (57.2 ± 30.8), p = 0.039; IL and NJ (62.0 ± 26.8), p = 0.007; between non-mandated states in aggregate (79.9 ± 19.9) and MA, p = 0.006, and NJ (62.0 ± 26.8), p = 0.02. Male factor rates of HI (65.8 ± 16.0) were significantly greater compared to CT (18.8 ± 8.7), IL (26.0 ± 11.9), MA (26.9 ± 6.6), MD (29.3 ± 9.9), NJ (30.6 ± 17.9), and non-mandated states in aggregate (29.7 ± 13.7), all p < 0.0001. No significant differences were reported for use of PGT and/or live birth rates across all age groups regardless of mandate status. Conclusions ICSI use varied significantly among ART-mandated states while demonstrating no differences in live birth rates. These data suggest that the prevalence of male factor and the presence of a state insurance mandate are not the only factors influencing ICSI use. It is suggested that other non-clinical factors may impact the rate of ICSI utilization in a given state.

Download Full-text

Differences in ICSI utilization rates among states with insurance mandates for ART coverage

Reproductive Biology and Endocrinology ◽

10.1186/s12958-021-00856-4 ◽

2021 ◽

Vol 19 (1) ◽

Author(s):

Pavel Zagadailov ◽

Kyung S. Cho ◽

David B. Seifer

Keyword(s):

Live Birth ◽

Statistical Significance ◽

Age Groups ◽

Bonferroni Correction ◽

Male Factor ◽

Birth Rates ◽

Preimplantation Genetic Testing ◽

Insurance Mandates ◽

Live Birth Rates ◽

Insurance Mandate

Abstract Background Assisted reproductive technology (ART) insurance mandates promote more selective utilization of ART clinic resources including intracytoplasmic sperm injection (ICSI). Our objective was to examine whether ICSI utilization differs by state insurance mandates for ART coverage and assess if such a difference is associated with male factor, preimplantation genetic testing (PGT), and/or live birth rates. Methods In this retrospective analysis of the Centers for Disease Control (CDC) data from 2018, ART clinics in ART-mandated states (n = 8, AR, CT, HI, IL, MD, MA, NJ, RI) were compared individually to one another and with non-mandated states in aggregate (n = 42) for use of ICSI, male factor, PGT, and live birth rates. ANOVA was used to evaluate differences between ART-mandated states and non-mandated states. Individual ART-mandated states were compared using Welch t-tests. Statistical significance was determined by Bonferroni Correction. Results There were significant differences in ICSI rates (%, mean ± SD) between MA (53.3 ± 21.3) and HI (90.7 ± 19.6), p = 0.028; IL (86.5 ± 18.7) and MA, p = 0.002; IL and MD (57.2 ± 30.8), p = 0.039; IL and NJ (62.0 ± 26.8), p = 0.007; between non-mandated states in aggregate (79.9 ± 19.9) and MA, p = 0.006, and NJ (62.0 ± 26.8), p = 0.02. Male factor rates of HI (65.8 ± 16.0) were significantly greater compared to CT (18.8 ± 8.7), IL (26.0 ± 11.9), MA (26.9 ± 6.6), MD (29.3 ± 9.9), NJ (30.6 ± 17.9), and non-mandated states in aggregate (29.7 ± 13.7), all p < 0.0001. No significant differences were reported for use of PGT and/or live birth rates across all age groups regardless of mandate status. Conclusions ICSI use varied significantly among ART-mandated states while demonstrating no differences in live birth rates. These data suggest that the prevalence of male factor and the presence of a state insurance mandate are not the only factors influencing ICSI use. It is suggested that other non-clinical factors may impact the rate of ICSI utilization in a given state.

Download Full-text